| Title | A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers |
| Protocole ID | OCEL-01 |
| ClinicalTrials.gov ID | NCT04260802 |
| Cancer Type(s) | Other |
| Phase | Phase I-II |
| Stage | Advanced or metastatic disease |
| Study Type | Treatment |
| Drug | OC-001 en monothérapie et en combination avec un anticorps Anti-PD-1/Anti-PD-L1 |
| Institution |
CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL
 HOPITAL GENERAL JUIF SIR MORTIMER B.DAVIS
3755 rue de la Côte Ste. Catherine, Montréal, QC, H3T 1E2 |
| City | |
| Principal Investigator |
Dr. Wilson Miller |
| Coordinator |
Ivgenya Kosenko 514-340-8222 poste 25981 |
| Status | Recruiting |
| Activation Date | |
| Eligibility Criteria | |
| Exclusion Criteria | |
Groupe d'étude en oncologie du Québec